Vivid Dx NEWS
Milestones on Our
Path to Clinical Impact
Vivid Dx has rapidly de-risked core technology and is now scaling toward clinical validation. Explore the milestones we’ve achieved and the catalysts driving our next phase of growth.
📍 June 2025
Vivid Dx Plans Capital Raise to Accelerate AST Development
Following strong pre-clinical results, Vivid Dx plans to raise £3M to accelerate phenotypic AST development.
TIMELINE
🧪 May 2025
Awarded £350k Biomedical Catalyst Grant
UKRI awards funding to support development of Vivid Dx’s rapid antimicrobial resistance testing system.
🔬 April 2024
£4M Committed by Oxford Science Enterprises (OSE)
OSE joins as lead investor to support Vivid Dx’s AI-powered Raman diagnostics platform.
📈 March 2024
92% Concordance Achieved with Gold-Standard AST
In a preclinical trial analyzing 64,000 single-cell spectra, Vivid Dx achieved 92% agreement with MIC-based AST methods.
🧠 December 2023
AI Engine Hits 99% Pathogen ID Accuracy in Lab Trials
Our proprietary deep learning model achieved 99% accuracy in species-level ID using Raman spectra — a first in the field.
⚙️ August 2023
First Working Prototype Demonstrated
The Vivid Dx system successfully identified pathogens direct-from-blood, bypassing the need for culture. First optical and sample prep modules validated.
🔜 What’s Next
Scale scientific, engineering & microfluidics capabilities
Finalize and deploy integrated proof-of-concept system
Conduct clinical validation with patient samples
Accelerate phenotypic AST development
